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Abstract
 .Maple syrup urine disease MSUD is an autosomal recessive disorder caused by defective function of the mitochondrial
 .branched chain a-ketoacid dehydrogenase BCKD complex. Mutations in both alleles of any of three genes for component
proteins result in the clinical phenotype. Two discrete mutant alleles for the E1b subunit of the decarboxylase component in
a proband with MSUD are defined and parental origin of each allele identified. The maternal mutation, an A to T
 .transversion at nucleotide 526 in the coding sequence, potentiates an asparagine to tyrosine change at position 126 N126Y .
 ) .The paternal mutant allele contains a C to T transition at nucleotide 970 introducing a stop codon R274 . Western blot
analysis revealed a 75% reduction in the E1b-N126Y protein and an absence of the R274) truncated protein in proband
cells. Both mutant proteins could be synthesized, imported into mitochondria, and processed in vitro. Functional analysis of
the mutant proteins provided new information on the role of E1b in the activity of BCKD. In vivo the E1b-N126Y protein
associated into macromolecular complexes indistinguishable from those formed with the wild type E1b protein. However,
catalytic activity of these complexes in proband cells was -1% of wild type activity. Alignment comparisons with other
thiamin pyrophosphate-requiring enzymes suggests the N126Y substitution could interfere with interactions of the protein
with the cofactor causing inactivity. The truncated E1b-R274) protein is unstable and not found in mitochondria from the
patient derived cells. q 1997 Elsevier Science B.V.
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1. Introduction
 .Maple syrup urine disease MSUD is inherited as
an autosomal recessive disorder resulting from de-
fects in both alleles of any of the genes encoding the
three catalytic subunits of the branched chain a-keto-
 . w xacid dehydrogenase BCKD complex 1,2 . A func-
tional relationship between the altered gene and the
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clinical phenotype is masked by the use of protein
modified diets in treatment of affected individuals,
which serves to suppress the phenotype. Still, molec-
ular biological analyses of altered protein structure
resulting from these mutations has provided structural
and functional information on two of the BCKD
w x  .proteins 3,4 . The role of the b subunit E1b of the
decarboxylase component remains to be clarified. To
date 40 different mutations have been described for
the three genes, but only five of these are specific to
the gene for E1b. Three of these result in early
0925-4439r97r$17.00 q 1997 Elsevier Science B.V. All rights reserved.
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termination of E1b , the fourth is a splice-site base
substitution and the fifth results in an amino acid
w xsubstitution, H156R 5,6 . Biochemical analysis of
the functional consequence for the E1b-H156R pro-
tein has not been reported and little is known about
the role of E1b within BCKD. Amino acid substitu-
tions within proteins that result in dysfunction are
most helpful in defining normal mechanisms of pro-
tein function.
BCKD is one member of the eukaryotic a-keto-
acid dehydrogenase family of mitochondrial multi-
component enzymes that catalyze key reactions in
intermediary metabolism of carbohydrates and
w xbranched chain amino acids 7 . Structural organiza-
tion and catalytic function are similar for the different
 .complexes that include pyruvate dehydrogenase PD
 .and a-ketoglutarate dehydrogenase KGD along with
w xBCKD 8 . Each complex is composed of a
 .substrate-specific decarboxylase E1 , an acyltrans-
 .ferase E2 and a flavoprotein, lipoamide dehydroge-
 .nase E3 , common to all three complexes. Activity
of the mammalian PD and BCKD is regulated by a
complex-specific kinase and phosphatase in a tissue
w xspecific manner 9 .
In the BCKD and PD complexes E1 is an a b2 2
tetramer, while in KGD this activity is found in a
homodimer. E1 activity requires the cofactor thiamin
 .pyrophosphate TPP to catalyze the release of CO2
from the a-ketoacid substrate. Domains within the a
and b proteins have been implicated in TPP binding
by analogy to other TPP-dependent enzymes such as
w xyeast transketolase 10,11 . In efforts to understand
better the role of E1b , we have identified two novel,
independent mutations in the alleles of the e1b gene
found in a compound heterozygote individual with
MSUD. Functional consequences of the altered pro-
teins were assessed. These studies provide the first
characterization of domains and amino acids that are
important for the function of E1b as part of the
BCKD complex.
2. Materials and methods
2.1. Cell culture
Peripheral blood lymphocytes from proband, par-
ents and control individuals were immortalized with
Epstein-Barr virus through services provided by the
Emory University Clinical Research Facility. These
lymphoblast cultures were maintained and propagated
at 378C in 5% atmospheric CO and RPMI 16402
medium supplemented with 15% fetal bovine serum.
2.2. Western blot
Mitochondria were isolated from approximately
7 w x5=10 lymphoblasts as previously described 12 .
Western blots, using a polyclonal antiserum against
w xpurified BCKD 13 , were visualized by chemilumi-
nescence with the ECL Western blotting system
 .Amersham . To quantify the amount of BCKD sub-
units in the different cell lines, autoradiographs of
serial dilution of the mitochondria were analyzed
using a molecular dynamics densitometer as previ-
w xously described 14 .
2.3. Whole cell BCKD acti˝ity assay
BCKD enzyme activity was determined by quanti-
14 w 14 xfying the release of CO from 1- C -leucine es-2
w xsentially as described 15 . Assays were done in
triplicate in the presence of 1 mM a-chloroiso-
caproate, a specific inhibitor of the BCKD-kinase,
allowing conversion of the complex to the unphos-
w xphorylated, fully active state 15 . Cellular protein
content was determined using the BCA protein assay
 .Pierce following the manufacturer’s instructions.
2.4. Complementation analysis by cell fusion
Human lymphoblast cell lines used for fusion anal-
ysis included: an E1a-defective cell line, EM 408
w x w x16 , an E2-deficient cell line, EM261 17 and the
proband cell line, EM1952. Fusion was done by a
w xmodification of the Kohler and Milstein method 18 .¨
Approximately 4.5=106 cells from each line were
combined and isolated by centrifugation at 400=g
for 5 min. Each set of cells was washed in 15 ml
1=PBS and resuspended in 1.35 ml of a 1:1 dilution
 .of 5 g PEG 1300–1600 Cell Culture grade, Sigma
dissolved in 10 ml of 1=PBS. Cells were incubated
at room temperature for 1 min and then diluted into
13 ml of RPMI 1640. Cells were collected by cen-
trifugation and washed with RPMI 1640 supple-
mented with 15% FBS, then isolated again and resus-
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pended in 10 ml of RPMI 1640 with 15% FBS. After
a 24 h incubation, a second fusion procedure was
done as above on the same cells, this time using the
undiluted PEG solution. Following the washes, cells
were resuspended in 6 ml of RPMI 1640 supple-
mented with 8% FBS and placed incubated for 72 h
prior to assaying for BCKD activity. Fused cells
contained approximately 10–15% polykaryons as de-
 .tected by Giemsa staining Sigma , with a median
value of four nuclei per fused cell. Enzyme activity
assays were done as described above.
2.5. Determination of BCKD transcript le˝els
Total RNA was isolated from lymphoblasts using
 .TRI reagent Molecular Research Center, Cincinnati
following the manufacturer’s instructions. The amount
of mRNA for specific BCKD transcripts was quanti-
fied by RNase protection analysis using subunit-
specific probes and conditions as previously de-
w xscribed 14,17 . Values for BCKD mRNA concentra-
tions were normalized to g-actin mRNA for each cell
preparation.
2.6. Sequencing of amplified cDNA and confirmation
of nucleotide change in genomic DNA
Moloney murine leukemia virus reverse transcrip-
 .tase Boehringer Mannheim, Indianapolis was used
to synthesize cDNA from 10 mg total cellular RNA
using random hexamer primers. Regions of the E1b
cDNA were amplified by PCR using Taq polymerase
 .Boehringer Mannheim and sequenced directly using
 .Sequenase Version 2.0 Amersham according to the
manufacturer’s instructions.
Nucleotide changes identified in the cDNA were
confirmed by analysis of genomic DNA prepared
from cultured cells derived from the proband and
parents. Allele specific hybridization using the fol-
 Xlow ing probes 5 C A A A A C A G G G C r
X.TGACTGCTAA3 was used to confirm the C T970
w32 xchange. Probes were end labeled with ATP-g P
using T4 polynucleotide kinase according to standard
w xprotocols 19 . Exon 9 of the E1b gene was ampli-
fied by PCR using genomic DNA as template and
appropriate intronic primers. The amplified fragment
was blotted to nylon membranes Schleicher and
.Schuell Dot Blot apparatus and the membranes
placed in prehybridization solution containing 10=
Denhardts, 200 mgrml salmon sperm DNA and 6=
SSC at 498C for 4 h. Next the membranes where
placed in fresh hybridization solution containing the
radiolabeled probes and incubation continued at 498C
overnight in a shaking water bath. Membranes were
then washed for 5 min at room temperature in 6=
SSC, 1% SDS followed by a second wash for 15 min
in the same solution and a third wash for 15 min in
1=SSC, 0.5% SDS at 428C. Hybridization was de-
tected using a Molecular Dynamics Phosphorimager.
2.7. Plasmid construction
DNA including nucleotides 3–1243 of the coding
region for human BCKD-E1b was ligated into
 .pGEM7zfq Promega for transcription from the T7
 .promoter pBMb new . The numbering scheme for
position of the nucleotide substitutions begins at the
1ATG start codon. A plasmid containing the T substi-
 .tution at position 526 pBMb mut1 was constructed
by replacing the Pst IrNcoI region of pBMb new
with the corresponding region from a cloned PCR
fragment containing the nucleotide change obtained
from the patient cDNA. Likewise, a plasmid contain-
 .ing the T at position 970 pBMb mut2 was con-
structed by replacing the NcoIrCsp45 I region of
pBMb new with the same region from a clone con-
taining the bp 970 substitution. Constructs were se-
quenced in the regions of the replacement cassettes to
ensure that only the desired nucleotide changes were
present.
2.8. In ˝itro transcriptionr translation and import
In vitro transcriptionrtranslation was done using
the TNT coupled reticulocyte lysate system Pro-
.mega with T7 polymerase. Proteins were labeled
35 35  .  .with S S cysteine 10 mCirml Amersham since
E1b contains only four methionine residues one of
which is lost on mitochondrial import and processing
of the pre-E1b protein. In vitro import of labeled
w xproteins was done essentially as described 12 .
2.9. Multi-protein complex analysis
Mitochondria were isolated from 2=108 cells and
resuspended in 750 ml of 50 mM potassium phos-
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phate, pH 7.4. This solution was frozen on dry ice,
thawed under cold water and then clarified by cen-
trifugation at 32,000=g for 30 min at 48C. The
supernatant was fractionated into 1 ml aliquots on a
 .Sephacryl S-200-HR column 1.5=36 cm equili-
brated with a buffer containing 50 mM potassium
phosphate, pH 7.4, 0.2 mM TPP and 0.2 M NaCl.
Proteins were precipitated from 400 ml aliquots of
w xeach fraction as described 19 and used for Western
blot analysis using a polyclonal antiserum that recog-
nized all components of the BCKD complex. Quanti-
ties of E1b protein were determined by densito-
metric analysis and blots were normalized to each
other by equal loadings of mitochondrial extracts
based on protein.
2.10. Protein alignment analysis
Analysis of homologous regions of multiple TPP-
binding proteins was done using the Wisconsin Se-
quence Analysis Package, Version 8.0 Genetics
.Computer Group . Alignments were made using com-
plete amino acid sequences from a-ketoglutarate E1
 .protein from Saccharomyces cere˝isiae m26390 and
 .Homo sapiens d10523 ; pyruvate dehydrogenase
 .E1b from Arabidopsis thaliana u09137 and Homo
 .sapiens m54788 ; BCKD E1b from Bacillus sub-
 .  .tilis m97391 , and Homo sapiens m55575 and
transketolase from Saccharomyces cere˝isiae
 .x73224 . Multiple sequence alignment was done us-
ing the PileUp algorithm.
3. Results
3.1. BCKD enzyme acti˝ity and implication of the
defecti˝e subunit
 .BCKD activity in lymphoblasts EM1952 from
the proband was -1% of that present in a wild-type
 .control cell line Table 1 confirming the clinical
diagnosis of MSUD. Immunoblot analysis of BCKD
proteins reflected reduced levels of E1a and E1b
proteins in cells from the proband and both parents
 .Fig. 1 . Estimation of the relative reduction revealed
the E1a and E1b proteins in the proband to be
approximately 57 and 25% of that present control
Table 1
BCKD activity in intact lymphoblasts from proband and control
aCell line Total activity % of control
14 .pmol CO rmg proteinrh2
Proband 17"6 0.4
Control 4130"537 100
a Values are the means"SD of triplicate determinations. Total
activity was obtained by inclusion of 0.1 mM a-chloroiso-
caproate to inhibit endogenous BCKD-kinase.
w xcells 14 . These two subunits also were reduced in
parental cells; E1a by about 20% and E1b by
nearly 50%. RNase protection analysis showed nor-
mal levels of the E1a and E2 transcripts in EM1952
cells. Two protection products for E1b were ob-
served: a shortened fragment and a normal size E1b
 .fragment Fig. 2 . The presence of a smaller sized
fragment suggested that a nucleotide mismatch oc-
curred in the mRNA region protected by the probe.
Both fragments were present in equal amounts and
the sum of these two equaled the amount of E1b
transcript in wild type cells. To test the hypothesis
that the mutations in the E1b gene are responsible of
the defective BCKD function, enzyme complementa-
tion analysis was done by cell fusion as described in
Section 2. Fusion of EM1952 cells with either an
E1a-defective or E2-deficient cell line restored
BCKD activity to the heterokaryon population. Self
fusion in all cases did not result in functional BCKD
 .Table 2 . No characterized E1b-deficient cell line
was available for test fusions.
Fig. 1. Western blot for proteins of the BCKD complex. Mito-
chondrial proteins from proband, parents and control lympho-
blasts were separated by SDS-PAGE and used for immunoblots
as described in Section 2. Positions of the BCKD subunits are
indicated at left. Subunit abundance reported in text were calcu-
lated relative to the E3 protein in each lane. This figure repre-
sents one of three independent determinations. Sequential dilu-
tions of mitochondrial protein loaded were used to quantify
subunit concentration. Only the 10 mg protein load is shown.
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3.2. Nucleotide sequence analysis of E1b in proband
and parents
Direct analysis of the nucleotide sequence for the
E1b coding region was done with cDNA prepared
from total RNA isolated from the various cell lines
and amplified in two sections. Two different single
nucleotide changes were found after analysis of the
entire coding sequence for E1b transcripts in
EM1952. An A to T transversion at nucleotide 526
predicted an amino acid substitution of tyrosine for
 .asparagine N126Y . This A T change was in exon526
5 within the area protected by the E1b probe used
for RNase protection analysis. RNase digestion at this
mismatch would account for the approximately 50
nucleotide shorter protected fragment found by this
 .analysis Fig. 2 . The other change was a C to T
transition at nucleotide 970 resulting in a premature
stop codon predicting truncation of the protein
 ).R274 . Full length mature human E1b has 342
amino acids. This base substitution occurred outside
the area protected by the E1b probe and thus ac-
counts for the correct size mRNA fragment for E1b
 .in proband cells Fig. 2 . These results imply the
proband was a compound heterozygote at the E1b
gene locus. To determine the origin and phase of the
Fig. 2. Autoradiograph of RNase protected transcripts for the
BCKD subunits. Probes for all subunits were within the coding
region for the mature proteins and are indicated by boxed areas
with the mRNA diagram beside each protected fragment. Tran-
script levels were compared in control and proband cells using 15
mg of total RNA. Full-size protected fragments are indicated on
the left; the smaller fragment produced with the E1b probe and
RNA from the proband is indicated on the right. Equal RNA
loading was confirmed by using a probe for g-actin. Probes and
w xconditions are previously described 14 .
Table 2
Intergenic complementation by cell fusion
Fused cell lines BCKD activity Fold change
14pmol CO rmg proteinrh after fusion2
1952=1952 34"6
408=408 6"3
261=261 206"32
1952=408 697"61 35
1952=261 701"111 5.8
408=261 594"17 5.6
Approximately 1.5=106 cells of each lymphoblast cell line were
self-fused or pair-fused as described in Section 2. Values for
BCKD activity are mean"SD as in Table 1. Fold change was
calculated by the activity after fusion divided by the average of
the activity in the two cell lines prior to fusion.
nucleotide changes, cDNA and genomic DNA from
the proband and parental cells was analyzed. Nu-
cleotide sequence analysis of cDNA revealed the
allele with the T substitution at position 970 was
contributed by the father and the T containing allele
 .at position 526 was maternally derived Fig. 3A . The
C T change was confirmed in genomic DNA by970
 .allele specific oligomer hybridization Fig. 3B . Al-
lele specific oligonucleotides for hybridization or PCR
amplification for the change from A to T at position
w x526 has met with the anticipated problems 20 for
changes of this type.
3.3. Translation and import of the altered E1b sub-
units
The reduced amount of E1b-N126Y protein in
mitochondria from the proband cells and the absence
of E1b-R274) was investigated by analysis of the in
vitro made proteins compared to wild-type. All three
proteins were synthesized with similar efficiency and
imported and processed to smaller size proteins that
 .were protected from proteolytic digestion Fig. 4 .
Although the E1b-R274) protein was not observed
by western blots of mitochondrial proteins from
proband or father, the in vitro made protein was
clearly detectable inside the mitochondria as a pro-
cessed protein. All three in vitro made proteins were
equally recognized by anti-BCKD antiserum Data
.not shown so the lack of detection in vivo was due
to the absence of protein and not an artifact of
antibody insensitivity. Since we do not have a cell
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Fig. 3. Analysis of nucleotide changes in the human gene for
 .E1b. A Nucleotide sequence of cDNA fragments reverse tran-
scribed and amplified from total RNA from the indicated cell
lines. As indicated the heterozygous A T transversion is pre-526
sent the in proband and mother, and the heterozygous C T970
 .transition is present in the proband and father. B Allele specific
oligonucleotide hybridization to a fragment of genomic DNA
from each family member and control for the C T change in970
exon 9.
line that lacks E1b it was impossible to do import
studies with mitochondria without endogenous E1b
protein.
3.4. Ability of E1b-N126Y to form BCKD complexes
The ability of E1b-N126Y to associate with the
other BCKD subunits was tested by analysis of the
BCKD complex through size fractionation of mito-
chondrial proteins. Protein content of fractions col-
lected from a Sephacryl S-200-HR column were ana-
Fig. 4. Mitochondrial import of the three forms of E1b proteins
made in vitro. Plasmids used were transcribed from the T7
promoter and translated using the TNT system as described in
Section 2. Radiolabled proteins detected by phosphorimaging.
Precursor proteins are indicated by solid arrows and imported and
processed proteins by open arrows.
Fig. 5. Size fractionation of BCKD complexes from control and
 .proband cells. Mitochondrial protein homogenates 175 mg from
each cell line were resolved on a Sephacryl S-200-HR size
 .calibrated column 1.5=36 cm as described in Section 2.
Molecular weight size markers are indicated across the top. The
full BCKD complex with an M )2=106 elutes with the voidr
volume around fraction 15. The predicted size of the a b2 2
tetramer is ;1.65=105 corresponding to the area around faction
35. Open symbols represent extracts from control cells and solid
symbols extracts from EM1952.
 .lyzed by Western blot Fig. 5 . All the BCKD pro-
teins were detected in the peak associated with elu-
tion patterns for the full complex. Only the a and b
proteins were detected in fractions eluting with an Mr
near 1.65=105 indicative of the a b tetamer.2 2
Distribution of the E1b proteins found in full com-
plex and in tetramers was similar in proband and
control cell extracts and like that seen for the purified
w xbovine BCKD 21 . Thus, E1b-N126Y protein in
EM1952 cells was able to form complexes with the
other BCKD components. Again, the putative trun-
cated protein was not detected in any of these analy-
ses.
3.5. Comparison of BCKD E1b with other TPP-bind-
ing proteins
Amino acid sequence alignments were done as
described in Section 2. Yeast transketolase was in-
cluded since the crystal structure is known for this
TPP-requiring enzyme, which has extensive similar-
ity to E1 proteins of the various a-ketoacid dehydro-
genase complexes. Progressive pairwise alignment
exposed a region that was highly conserved among
( )B.B. McConnell et al.rBiochimica et Biophysica Acta 1361 1997 263–271 269
 .Fig. 6. Alignment of enzymes using TPP as a cofactor. For details see Section 2. Shown are human BCKD-E1b BCKD HUM , B.
 .  .  . subtilis BCKD-E1b BCKD SUB , human PD-E1b PDH HUM , A. thaliana PD-E1b PDH ARAB , S. cere˝isiae KGD-E1 KGD
.  .  .YST , human KGD-E1 KGD HUM and S. cere˝isiae transketolase TKL YST . Amino acid N126 in human BCKD-E1b is starred.
Residues in transketolase involved in forming the hydrophobic TPP binding pocket for the thiazolium ring are in bold. Catalytic residues
in transketolase are denoted by arrows.
 .all these proteins Fig. 6 . Crystallographic analysis
w xof the transketolase 22 identified functionally im-
portant amino acids in this region that included a
hydrophobic pocket that binds the pyrimidine ring of
TPP formed by F442, F445 and Y448 with residues
E418 and H481 involved in proton abstraction. Simi-
lar residues were found in the BCKD-E1b protein at
positions E76, F99, Y102, F104 and H146. The
N126Y substitution lies within this region essential
for positioning of the functionally important histidine
and phenylalanine residues.
4. Discussion
Although mutations within the human E1b gene
are associated with dysfunctional BCKD and the
clinical phenotype of MSUD, a biochemical basis for
w xthe dysfunction has not yet been described 5,6 .
Likewise, a functional role for E1b within the BCKD
complex has not been assigned. Here we take advan-
tage of two new mutant alleles in this gene to begin
addressing the function of E1b within the complex.
One allele introduces a premature stop codon due to a
C T transition that potentially truncates E1b at970
R274, shortening the protein by 68 amino acids.
Transcript for E1b R274) is as abundant as the full
length transcript in cells from this compound het-
 .erozygous proband Fig. 2 . However, no immunore-
active protein of appropriate size was detected in
mitochondria from the proband or her father, al-
though in vitro translation experiments demonstrated
the E1b R274) was antigenic and could be imported
and processed to remove the MTS. Since it has
previously been shown that both E1a and E1b pro-
teins are stabilized by formation of the a b te-2 2
tramer, our results suggest that domains or amino
acids within the last 68 residues of E1b are neces-
w xsary for tetramer formation 23 . In support of this
w xidea, Nobukuni et al. 6 described an allele in an
MSUD patient that potentially truncated E1b at S269
due to a T deletion. Again no immunoreactive954
protein of appropriate size was detected in mitochon-
dria from that proband. Direct testing for interaction
of an in vitro made truncated E1b protein with the
E1a subunit remains to be done.
The protein product of the other allele,
E1b N126Y, is present in the mitochondria although
in reduced amounts. We have shown previously that
the amount of E1b can influence the amount of total
w xcomplex found in a mitochondrion 14 . Reduced
total amount of complex will contribute to lower
activity of the BCKD complex within a cell but if the
complex is functional the MSUD phenotype should
not occur. Indeed, the obligate heterozygous parental
cell lines show reduced E1b protein, but retain
enough BCKD activity to prevent a phenotype of
MSUD. It was not possible to determine whether all
the E1b forming the BCKD complex in maternal
cells was wild-type or a mixture of the two forms.
Since E1 is an a b tetramer, carious combinations2 2
are possible. The non-functional E1b N126Y protein
may have a higher degradation rate as suggested by
the reduced amount found in proband cells which
only has the E1b N126Y protein. Molecular sieve
fractionation of the BCKD complex found in the
mitochondria of the proband cells demonstrated that
the E1b N126Y protein does form a b tetramers2 2
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and these can associate with the other subunits to
 .form the BCKD complex Fig. 6 . Thus, the inactiv-
ity of BCKD in these cells must be the result of the
asparagine to tyrosine change at position 126 within
 .E1b Table 1 .
Decarboxylation activity attributed to the E1 sub-
unit depends on the binding of the TPP–Mg2q cofac-
tor. Initial studies done with the PD complex sug-
gested that only the a subunit of the a b tetramer2 2
bound TPP and the critical peptide sequence was
 . w xGDG X NN 10 . These authors showed thatn
BCKD-E1a did align with the other TPP requiring
enzymes for this motif. Recent data has demonstrated
that the TPP binding site for PD-E1 is formed by
amino acids residues in both a and b subunits
w x11,24–26 . Although crystallographic structure for
the E1 component of any mammalian ketoacid dehy-
drogenase complex has not been solved, the crystal
structure for yeast transketolase has been extensively
w xanalyzed 22,27 . Analogies between transketolase
and PD-E1 have been used to define the critical
w xamino acids that form the TPP pocket 11 . Compar-
ing the amino acid sequence of BCKD-E1b with the
peptide sequence of other E1b proteins and transke-
 .tolase provided some striking similarities Fig. 6 .
Glutamic acid 76, F99 and H 146 of BCKD-E1b
align with identical residues used by the other pro-
teins in binding TPP. At position 101 in BCKD-E1b
is found a Y while the corresponding position in the
other proteins is F. Using Robinson’s alignment of
 w x.PD-E1b Fig. 2 in 11 , BCKD-E1b has a critical E
30 residues N-terminal to the E that begins the
alignment seen in Fig. 6. This pocket appears to serve
the function of exposing only the C2 position of the
thiazolium ring of TPP to solvent, establishing the
w xreactive site for substrate binding 28 . Studies with
PD-E1 have revealed that it is not necessary to
mutate only these amino acids involved in binding to
alter catalytic activity. Altering R239 or W135 of
w xPD-E1b leads to inactive E1 25,26 . Thus, it is not
surprising that the N126Y mutation reported here
results in inactivity of BCKD. We have not yet been
able to demonstrate whether the loss of activity is due
to a lack of TPP binding or a blockage of the reactive
C2X carbon of the thiazolium ring. Wikner et al.
showed that if transketolase E418 is mutated, TPP
still binds but is catalytically inactive suggesting a
w xsimilar fate for this BCKD-E1b mutation 29 . It
should be pointed out that our alignment differs from
one reported earlier comparing transketolase with
w xBCKD-E1b 30 . This difference may be the result
of the other group using fewer proteins in the com-
parisons and their exclusion of PD-E1b and KGD-E1
proteins. It will be interesting to learn whether muta-
tions resulting in amino acid substitutions throughout
E1b result in inactive BCKD as already observed
with the E1a subunit.
In summary, we have identified two naturally oc-
curring mutations in BCKD-E1b. One provides evi-
dence of a catalytic function for E1b in human
BCKD and suggests a region of the protein that is
important for TPP binding and catalysis. The second
mutation results in a protein that lacks the last 68
amino acids. This truncated protein does not accumu-
late in the mitochondria, suggesting that this region is
important for stability of the E1b protein through its
interaction with E1a in forming the decarboxylase
subunit.
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